LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 202

Search options

  1. Article ; Online: The diagnostic likelihood ratio function and modified test for trend: Identifying, evaluating, and validating nontraditional biomarkers in case-control studies.

    Lindner, Hanna / Gimotty, Phyllis A / Bilker, Warren B

    Statistics in medicine

    2023  Volume 42, Issue 29, Page(s) 5313–5337

    Abstract: The ROC curve and its associated summary statistic, the AUC, are used to identify informative diagnostic biomarkers under the assumption that risk of disease is a monotone function of the biomarker. We refer to biomarkers that meet this assumption as ... ...

    Abstract The ROC curve and its associated summary statistic, the AUC, are used to identify informative diagnostic biomarkers under the assumption that risk of disease is a monotone function of the biomarker. We refer to biomarkers that meet this assumption as traditional, and those that do not as nontraditional. Nontraditional biomarkers most often arise when both low and high biomarker values are associated with an outcome of interest, such as blood pressure with medical complications or leukocyte count with ICU prognosis. Since nontraditional biomarkers do not meet the assumptions for ROC-based analyses, we propose using the discrete diagnostic likelihood ratio (DLR) function to evaluate a wider class of informative biomarkers. We obtain the DLR function using the multinomial logistic regression (MLR) model to improve upon existing estimation techniques, and implement a likelihood ratio test to identify candidate informative traditional and nontraditional biomarkers. We propose a modification of the Cochran-Armitage test for trend that separates biomarkers deemed informative into traditional and nontraditional categories. The statistical properties of the likelihood ratio test and modified test for trend are explored under simulation. Together, these methods achieve the identification, evaluation, and validation of biomarkers from early discovery research. Finally, we show that incorporating covariates into the MLR model results in a covariate-adjusted DLR function that is useful for integrating multiple sources of information in clinical decision making. The methods are applied to gene expression data from subjects with high grade serous ovarian cancer, where stage, early stage vs late stage, is the outcome of interest.
    MeSH term(s) Humans ; Biomarkers ; Blood Pressure ; Case-Control Studies ; Clinical Decision-Making ; Likelihood Functions ; ROC Curve
    Chemical Substances Biomarkers
    Language English
    Publishing date 2023-09-21
    Publishing country England
    Document type Journal Article
    ZDB-ID 843037-8
    ISSN 1097-0258 ; 0277-6715
    ISSN (online) 1097-0258
    ISSN 0277-6715
    DOI 10.1002/sim.9912
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis.

    Brown, Timothy J / Mamtani, Ronac / Gimotty, Phyllis A / Karasic, Thomas B / Yang, Yu-Xiao

    Journal of cancer research and clinical oncology

    2023  Volume 149, Issue 6, Page(s) 2345–2354

    Abstract: Purpose: Hepatocellular carcinoma (HCC) is a common and deadly form of liver cancer. Combination atezolizumab and bevacizumab has improved the outcomes for patients with advanced disease. We sought to determine the impact of etiology on outcomes of ... ...

    Abstract Purpose: Hepatocellular carcinoma (HCC) is a common and deadly form of liver cancer. Combination atezolizumab and bevacizumab has improved the outcomes for patients with advanced disease. We sought to determine the impact of etiology on outcomes of patients treated with atezolizumab and bevacizumab.
    Methods: This study used a real-world database. The primary outcome was overall survival (OS) by etiology of HCC; the secondary outcome was real-world time to treatment discontinuation (rwTTD). Time-to-event analyses was performed by the Kaplan-Meier method; the log-rank test to assess for differences by etiology from date of first receipt of atezolizumab and bevacizumab. The Cox proportional hazards model was used to calculate hazard ratios.
    Results: In total, 429 patients were included (n = 216 Viral-HCC; n = 68 Alcohol-HCC; n = 145, NASH-HCC). The median overall survival for the entire cohort was 9.4 months (95% CI 7.1-10.9). Compared with Viral-HCC, the hazard ratio (HR) of death was 1.11 (95% CI 0.74-1.68, p = 0.62) for Alcohol-HCC and was 1.34 (95% CI 0.96-1.86, p = 0.08) for NASH-HCC. The median rwTTD for the entire cohort was 5.7 months (95% CI 5.0-7.0 months). The HR of rwTTD was 1.24 (95% CI 0.86-1.77, p = 0.25) for Alcohol-HCC and was 1.31 (95% CI 0.98-1.75, p = 0.06) in reference to TTD with Viral-HCC.
    Conclusions: In this real-world cohort of patients with HCC receiving first-line atezolizumab and bevacizumab, we did not identify an association between etiology and OS or rwTTD. This suggests that the efficacy of atezolizumab and bevacizumab may be similar across HCC etiologies. Further prospective studies are needed to confirm these findings.
    MeSH term(s) Humans ; Bevacizumab ; Carcinoma, Hepatocellular/drug therapy ; Non-alcoholic Fatty Liver Disease ; Liver Neoplasms/drug therapy ; Ethanol
    Chemical Substances Bevacizumab (2S9ZZM9Q9V) ; atezolizumab (52CMI0WC3Y) ; Ethanol (3K9958V90M)
    Language English
    Publishing date 2023-03-02
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 134792-5
    ISSN 1432-1335 ; 0171-5216 ; 0084-5353 ; 0943-9382
    ISSN (online) 1432-1335
    ISSN 0171-5216 ; 0084-5353 ; 0943-9382
    DOI 10.1007/s00432-023-04590-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Outcomes of Single Node Excision Compared with Lymph Node Dissection for Patients with Clinical Stage III N1b Cutaneous Melanoma.

    Sharon, Cimarron E / Tortorello, Gabriella N / Gimotty, Phyllis A / Beasley, Georgia M / Slingluff, Craig L / Miura, John T / Karakousis, Giorgos C

    Annals of surgical oncology

    2023  Volume 30, Issue 4, Page(s) 1956–1959

    MeSH term(s) Humans ; Melanoma/surgery ; Melanoma/pathology ; Skin Neoplasms/surgery ; Skin Neoplasms/pathology ; Lymph Node Excision ; Sentinel Lymph Node Biopsy ; Neoplasm Staging ; Lymph Nodes/surgery ; Lymph Nodes/pathology ; Retrospective Studies ; Melanoma, Cutaneous Malignant
    Language English
    Publishing date 2023-01-16
    Publishing country United States
    Document type Letter
    ZDB-ID 1200469-8
    ISSN 1534-4681 ; 1068-9265
    ISSN (online) 1534-4681
    ISSN 1068-9265
    DOI 10.1245/s10434-022-12999-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Conditional survival estimates for merkel cell carcinoma reveal the dynamic nature of prognostication.

    Miura, John T / Lindner, Hannah / Karakousis, Giorgos C / Sharon, Cimarron E / Gimotty, Phyllis A

    Journal of surgical oncology

    2022  Volume 126, Issue 2, Page(s) 348–355

    Abstract: Background and objectives: Conditional survival (CS) analysis has emerged as a dynamic prognostication methodology. The goal of this study was to determine disease-specific CS rates in Merkel cell carcinoma (MCC).: Methods: This retrospective study ... ...

    Abstract Background and objectives: Conditional survival (CS) analysis has emerged as a dynamic prognostication methodology. The goal of this study was to determine disease-specific CS rates in Merkel cell carcinoma (MCC).
    Methods: This retrospective study included patients with MCC from the Surveillance Epidemiology and End Results (SEER) registry (1988-2016). Stage-specific 5-year MCC-specific CS rates for study and survivor cohorts were estimated, and the significance of clinicopathologic factors to predict 1-year MCC-specific death was evaluated using multivariate logistic regression.
    Results: Within stage, 5-year CS survival rates improved with increasing survivorship. Pathologic Stage I patients had the highest 5-year CS rate at diagnosis (89.1%) but the smallest increase over time (96% among 5-year survivors). Stage IV patients experienced the greatest change in 5-year CS rates from 25.4% (at diagnosis) to 88% (5-year survivors). At diagnosis stage, age, sex, and primary site were all significantly associated with 1-year MCC-related death in the multivariate analysis. In contrast, among 5-year survivors only sex and age at diagnosis were significant predictors.
    Conclusions: MCC CS rates improved across all disease stages over time. Additionally, the relationships of prognostic factors with 1-year MCC-death changed with increasing survivorship. This perspective can provide a foundation for informed decision-making.
    MeSH term(s) Carcinoma, Merkel Cell ; Humans ; Neoplasm Staging ; Prognosis ; Retrospective Studies ; SEER Program ; Skin Neoplasms/pathology ; Survival Analysis
    Language English
    Publishing date 2022-03-22
    Publishing country United States
    Document type Journal Article
    ZDB-ID 82063-5
    ISSN 1096-9098 ; 0022-4790
    ISSN (online) 1096-9098
    ISSN 0022-4790
    DOI 10.1002/jso.26861
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Effects of neoadjuvant zoledronate and radiation therapy on cell survival, cell cycle distribution, and clinical status in canine osteosarcoma.

    Norquest, Carissa J / Rogic, Anita / Gimotty, Phyllis A / Maitz, Charles A / Rindt, Hansjorg / Ashworth, Hayley L / Bryan, Jeffrey N / Donnelly, Lindsay L / McCleary-Wheeler, Angela L / Flesner, Brian K

    Frontiers in veterinary science

    2024  Volume 11, Page(s) 1237084

    Abstract: Introduction: Zoledronic acid (ZOL) is a third-generation bisphosphonate with a higher affinity for bone resorption areas than earlier bisphosphonates (i.e., pamidronate, PAM). In human medicine, ZOL provides improved bone pain relief and prolonged time ...

    Abstract Introduction: Zoledronic acid (ZOL) is a third-generation bisphosphonate with a higher affinity for bone resorption areas than earlier bisphosphonates (i.e., pamidronate, PAM). In human medicine, ZOL provides improved bone pain relief and prolonged time to skeletal-related events compared to its older generational counterparts. Preclinical studies have investigated its role as an anti-neoplastic agent, both independently and synergistically, with radiation therapy (RT). ZOL and RT act synergistically in several neoplastic human cell lines: prostate, breast, osteosarcoma, and fibrosarcoma. However, the exact mechanism of ZOL's radiosensitization has not been fully elucidated.
    Methods: We investigated ZOL's ability to induce apoptosis in canine osteosarcoma cell lines treated with various doses of megavoltage external beam radiotherapy. Second, we evaluated cell cycle arrest in ZOL-treated cells to assess several neo-adjuvant time points. Finally, we treated 20 dogs with naturally occurring appendicular OS with 0.1 mg/kg ZOL IV 24 h before receiving 8 Gy of RT (once weekly fraction x 4 weeks).
    Results: We found that apoptosis was increased in all ZOL-treated cell lines compared to controls, and the combination of ZOL and RT resulted in dissimilar apoptosis between Abrams and D-17 and HMPOS cell lines. Cell cycle arrest (G2/M phase) was minimal and variable between cell lines but perhaps greatest at 48 h post-ZOL treatment. Only 10% of dogs treated with ZOL and RT developed pathologic fractures, compared to 44% of dogs historically treated with PAM and RT (
    Discussion: ZOL and RT appear to be a well-tolerated combination treatment scheme for non-surgical candidates; future studies must elucidate the ideal timing of ZOL.
    Language English
    Publishing date 2024-01-31
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2834243-4
    ISSN 2297-1769
    ISSN 2297-1769
    DOI 10.3389/fvets.2024.1237084
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: A novel pipeline for prioritizing cancer type-specific therapeutic vulnerabilities using DepMap identifies PAK2 as a target in head and neck squamous cell carcinomas.

    Sannigrahi, Malay K / Cao, Austin C / Rajagopalan, Pavithra / Sun, Lova / Brody, Robert M / Raghav, Lovely / Gimotty, Phyllis A / Basu, Devraj

    Molecular oncology

    2023  Volume 18, Issue 2, Page(s) 336–349

    Abstract: There is limited guidance on exploiting the genome-wide loss-of-function CRISPR screens in cancer Dependency Map (DepMap) to identify new targets for individual cancer types. This study integrated multiple tools to filter these data in order to seek new ... ...

    Abstract There is limited guidance on exploiting the genome-wide loss-of-function CRISPR screens in cancer Dependency Map (DepMap) to identify new targets for individual cancer types. This study integrated multiple tools to filter these data in order to seek new therapeutic targets specific to head and neck squamous cell carcinoma (HNSCC). The resulting pipeline prioritized 143 targetable dependencies that represented both well-studied targets and emerging target classes like mitochondrial carriers and RNA-binding proteins. In total, 14 targets had clinical inhibitors used for other cancers or nonmalignant diseases that hold near-term potential to repurpose for HNSCC therapy. Comparing inhibitor response data that were publicly available for 13 prioritized targets between the cell lines with high vs. low dependency on each target uncovered novel therapeutic potential for the PAK2 serine/threonine kinase. PAK2 gene dependency was found to be associated with wild-type p53, low PAK2 mRNA, and diploid status of the 3q amplicon containing PAK2. These findings establish a generalizable pipeline to prioritize clinically relevant targets for individual cancer types using DepMap. Its application to HNSCC highlights novel relevance for PAK2 inhibition and identifies biomarkers of PAK2 inhibitor response.
    MeSH term(s) Humans ; Squamous Cell Carcinoma of Head and Neck/drug therapy ; Squamous Cell Carcinoma of Head and Neck/genetics ; Protein Serine-Threonine Kinases ; Head and Neck Neoplasms/drug therapy ; Head and Neck Neoplasms/genetics ; Cell Line, Tumor ; p21-Activated Kinases/genetics
    Chemical Substances Protein Serine-Threonine Kinases (EC 2.7.11.1) ; PAK2 protein, human (EC 2.7.11.1) ; p21-Activated Kinases (EC 2.7.11.1)
    Language English
    Publishing date 2023-12-13
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2415106-3
    ISSN 1878-0261 ; 1574-7891
    ISSN (online) 1878-0261
    ISSN 1574-7891
    DOI 10.1002/1878-0261.13558
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: ASO Author Reflection: Sentinel Lymph Node Biopsy in Thin Melanoma.

    Sinnamon, Andrew J / Gimotty, Phyllis A / Karakousis, Giorgos C / Yang, Yu-Xiao

    Annals of surgical oncology

    2020  Volume 27, Issue Suppl 3, Page(s) 901–902

    MeSH term(s) Humans ; Melanoma/surgery ; Sentinel Lymph Node/surgery ; Sentinel Lymph Node Biopsy ; Skin Neoplasms/surgery
    Keywords covid19
    Language English
    Publishing date 2020-08-24
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1200469-8
    ISSN 1534-4681 ; 1068-9265
    ISSN (online) 1534-4681
    ISSN 1068-9265
    DOI 10.1245/s10434-020-09029-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: The pseudokinase Trib1 regulates the transition of exhausted T cells to a KLR

    McClory, Susan E / Bardhan, Oishi / Rome, Kelly S / Giles, Josephine R / Baxter, Amy E / Xu, Lanwei / Gimotty, Phyllis A / Faryabi, Robert B / Wherry, E John / Pear, Warren S / Jordan, Martha S

    bioRxiv : the preprint server for biology

    2023  

    Abstract: T cell exhaustion ( ... ...

    Abstract T cell exhaustion (T
    Language English
    Publishing date 2023-02-16
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2023.02.16.528833
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Interpreting the Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma-Reply.

    Sinnamon, Andrew J / Gimotty, Phyllis A / Karakousis, Giorgos C

    JAMA oncology

    2018  Volume 4, Issue 8, Page(s) 1136–1137

    MeSH term(s) Humans ; Melanoma ; Skin Neoplasms
    Language English
    Publishing date 2018-07-16
    Publishing country United States
    Document type Letter ; Comment
    ISSN 2374-2445
    ISSN (online) 2374-2445
    DOI 10.1001/jamaoncol.2018.0898
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Author Correction: Stiff matrix induces exosome secretion to promote tumour growth.

    Wu, Bin / Liu, Di-Ao / Guan, Lei / Myint, Phyoe Kyawe / Chin, LiKang / Dang, Hien / Xu, Ye / Ren, Jinqi / Li, Ting / Yu, Ziyan / Jabban, Sophie / Mills, Gordon B / Nukpezah, Jonathan / Chen, Youhai H / Furth, Emma E / Gimotty, Phyllis A / Wells, Rebecca G / Weaver, Valerie M / Radhakrishnan, Ravi /
    Wang, Xin Wei / Guo, Wei

    Nature cell biology

    2024  Volume 26, Issue 3, Page(s) 490–491

    Language English
    Publishing date 2024-02-12
    Publishing country England
    Document type Published Erratum
    ZDB-ID 1474722-4
    ISSN 1476-4679 ; 1465-7392
    ISSN (online) 1476-4679
    ISSN 1465-7392
    DOI 10.1038/s41556-024-01375-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top